Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by bilosellhion Aug 27, 2004 12:23am
374 Views
Post# 7856242

RE: so mcarter4/bilo had these posts removed

RE: so mcarter4/bilo had these posts removedthanks Chief. some here (who haven't gone way back in my posting history) may be surprised to learn that i was once very supportive of management of an up & coming calgary tech company called global thermoelectric. it would be fair, if not an understatement, to say that the Chief & i had a few differences of opinion that lasted a couple of years about how capable gle management was to take their fuel cell & company to the next level. it turned out that i was wrong about gle management and my support of them, and the Chief was right. i learned a lesson from that, and was fortunate that all it cost me was lost profits as opposed to actual losses, (i do try to live up to my "bilo" moniker , but i pledged not to make the mistake of confusing a breakthrough product with good management again. so far onc seems to be following the same path as gle - breakthrough technology/product that attracted the early interest of a large multinational company (delphi & pfizer) only to see them both walk without any explanation, followed by management inability to follow through & deliver on the promise & potential, at least outside of calgary. i hope onc & BT proves me wrong, but the longer they don't, the less confidence i have in current onc management making the final delivery, and i didn't have much to start (might have something to do with another calgary company called synsorb) i do expect to make money on onc, perhaps a lot depending on how good the clincial results eventually turn out to be (if they ever manage to get results from those small trials), and the hype that most surely will follow their release, but the larger question of whether BT & MC have the ability to actually deliver will imo, continue to loom large over this stock for as long as they "control" reolysin & the company. the fact that a heretofore benign virus with breakthrough cancer killing properties has only an 18 patient ph I safety trial and a 6 patient ph II prostate trial completed in 6 years since discovery is not suggestive that these guys can deliver, imo. maybe the science will yet overcome management's obvious shortcomings, but to ignore such a glaring weakness & risk relating to my investment would be folly. then again, given that some here think that baba & i are the same person solely by the timing of one evening's worth of posts, the greater "folly" theory seems to be alive & well.
Bullboard Posts